Compare Charles River Laboratories Intl. Inc (CRL) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Hilton Hotels Corporation Common Stock — how do they compare? Charles River Laboratories Intl. Inc trades at $231 (market cap $11.14B), while Hilton Hotels Corporation Common Stock trades at $326 (market cap $74.18B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 6.7× Charles River Laboratories Intl. Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.18% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | HLT | |
|---|---|---|
Market Cap | $11.14B | $74.18B |
Sector | Health | Consumer Cyclical |
52-Week High | $233.60 | $350.22 |
52-Week Low | $145.57 | $256.75 |
Enterprise Value | $14.00B | $86.68B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Hilton Worldwide (HLT) trades at $322.45, down 3.88% amid bearish technical signals, though it maintains strong fundamentals with consistent earnings beats and revenue growth to $12.04B in 2025. Analyst consensus remains bullish with a $340.50 price target, supported by 55% buy ratings. Recent news highlights brand campaigns and renovations, while financials show robust cash flow but rising debt levels.
The stock offers upside to analyst targets but faces near-term technical pressure and leverage concerns. Investment appeal hinges on execution of growth initiatives and debt management, with risks including economic sensitivity and competitive pressures in the hospitality sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
